Another randomized phase II clinical trial investigates the role of [sup.153]Sm-EDTMP (
Quadramet) with or without a PSA/TRICOM vaccine in men with androgen-insensitive metastatic prostate cancer.
The most commonly used radiopharmaceuticals, both [beta]-emitters, initially approved in the US for treatment of bone metastases are Strontium-89 chloride or 89Sr (Metastron; GE Healthcare, Arlington Heights, IL) and Samarium-153 or 153Sm (
Quadramet; EUSA Pharma, Oxford, UK).
Cytogen has also developed
Quadramet, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which the company receives royalties on product sales through Berlex Laboratories, the United States affiliate of Schering AG Germany, which markets the product in the United States.
Currently marketed products include ProstaScint (a monoclonal antibody- based imaging agent used to image the extent and spread of prostate cancer); BrachySeed I-125 and Pd-103 (two uniquely designed, next- generation radioactive seed implants for the treatment of localized prostate cancer); and
Quadramet (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer).
FDA-approved products include ProstaScint (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and Pd-103 (uniquely designed, next-generation radioactive seed implants for the treatment of localized prostate cancer); and
Quadramet (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer).
In oncology, FDA-approved products include ProstaScint (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(tm) (a uniquely designed next-generation radioactive seed implant for the treatment of localized prostate cancer),
Quadramet (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer), and OncoScint CR/OV (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer).
Currently marketed products include ProstaScint (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed I-125 and Pd-103 (two uniquely designed next-generation radioactive seed implants for the treatment of localized prostate cancer), and
Quadramet (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer).